They‘re working on a way out of their funding predicament, so they can initiate the Proof-of-Concept study for iTR. If there is a near-term catalyst, remains to be seen. The study itself might not inspire confidence until its results are published. But any strategic move that would allow them to clearly get on with it, could already lift the stock, as could a sale of some assets, like the iCM platform (induced cancer maturation), but it might not be ready yet. Mike said, they had no intention of entering the cancer field. The technology is basically a byproduct of their research on aging. Any progress with one of their existing collaborations could also help.
News 
Market Data 
Discover 
AI
